{"id": "article-22025_0", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Continuing Education Activity", "content": "Galactosemia is an inborn error of metabolism due to impaired degradation of galactose. If not recognized and treated promptly, affected infants may develop significant morbidity within days of birth. Newborn screening tests in developed countries have helped identify affected infants early. However, providers must maintain a high index of suspicion in ill newborns as feeding intolerance, hepatomegaly, lethargy, coagulopathy, and renal dysfunction may occur within the first few days of life, even before newborn screening tests have been finalized. This activity reviews the workup of a patient with suspected galactosemia and the role of the interprofessional team in managing this condition.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Continuing Education Activity. Galactosemia is an inborn error of metabolism due to impaired degradation of galactose. If not recognized and treated promptly, affected infants may develop significant morbidity within days of birth. Newborn screening tests in developed countries have helped identify affected infants early. However, providers must maintain a high index of suspicion in ill newborns as feeding intolerance, hepatomegaly, lethargy, coagulopathy, and renal dysfunction may occur within the first few days of life, even before newborn screening tests have been finalized. This activity reviews the workup of a patient with suspected galactosemia and the role of the interprofessional team in managing this condition."}
{"id": "article-22025_1", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Continuing Education Activity", "content": "Objectives: Describe the pathophysiology of galactosemia. Summarize how galactosemia is diagnosed early. Outline the signs and symptoms of galactosemia. Review the workup of a patient with suspected galactosemia and the role of the interprofessional team in managing this condition. Access free multiple choice questions on this topic.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Continuing Education Activity. Objectives: Describe the pathophysiology of galactosemia. Summarize how galactosemia is diagnosed early. Outline the signs and symptoms of galactosemia. Review the workup of a patient with suspected galactosemia and the role of the interprofessional team in managing this condition. Access free multiple choice questions on this topic."}
{"id": "article-22025_2", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Introduction", "content": "Galactosemia is an inborn error of metabolism due to impaired degradation of galactose.\u00a0The disease was first described in\u00a01917, and defective galactose metabolism was explained\u00a0as the cause in the 1950s. If not recognized and treated promptly, affected infants may develop significant morbidity within days of birth. Newborn screening tests in developed countries have helped identify affected infants early. However, providers must maintain a high index of suspicion in ill newborns as feeding intolerance, hepatomegaly, lethargy, coagulopathy, and renal dysfunction may occur within the first few days of life, even before newborn screening tests have been finalized. [1] [2] [3]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Introduction. Galactosemia is an inborn error of metabolism due to impaired degradation of galactose.\u00a0The disease was first described in\u00a01917, and defective galactose metabolism was explained\u00a0as the cause in the 1950s. If not recognized and treated promptly, affected infants may develop significant morbidity within days of birth. Newborn screening tests in developed countries have helped identify affected infants early. However, providers must maintain a high index of suspicion in ill newborns as feeding intolerance, hepatomegaly, lethargy, coagulopathy, and renal dysfunction may occur within the first few days of life, even before newborn screening tests have been finalized. [1] [2] [3]"}
{"id": "article-22025_3", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Etiology", "content": "The GALT gene on chromosome 9p13 encodes for galactose-1-phosphate uridylyltransferase, which is responsible for metabolizing galactose-1-phosphate to UDP-galactose. Deficiency of the enzyme leads to classic galactosemia. The GALK1 gene on chromosome 17q24 encodes for galactokinase, which is responsible for metabolizing galactose to galactose-1-phosphate. The GALE gene on chromosome 1p36-p35 encodes for UDP-galactose 4-epimerase, which is responsible for metabolizing UDP-galactose to UDP-glucose for use in glycogenesis. Inheritance is autosomal recessive, so both parents must be carriers, and offspring have a 25% chance of having clinical symptoms. Carriers do not typically demonstrate symptoms. [1]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Etiology. The GALT gene on chromosome 9p13 encodes for galactose-1-phosphate uridylyltransferase, which is responsible for metabolizing galactose-1-phosphate to UDP-galactose. Deficiency of the enzyme leads to classic galactosemia. The GALK1 gene on chromosome 17q24 encodes for galactokinase, which is responsible for metabolizing galactose to galactose-1-phosphate. The GALE gene on chromosome 1p36-p35 encodes for UDP-galactose 4-epimerase, which is responsible for metabolizing UDP-galactose to UDP-glucose for use in glycogenesis. Inheritance is autosomal recessive, so both parents must be carriers, and offspring have a 25% chance of having clinical symptoms. Carriers do not typically demonstrate symptoms. [1]"}
{"id": "article-22025_4", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Etiology", "content": "Duarte galactosemia is a variant of galactosemia due to diminished galactose-1-phosphate uridylyltransferase enzyme\u00a0activity (typically around 14% to 25%). Individuals born with Duarte variant\u00a0galactosemia are thought to be asymptomatic with or without dietary intervention, and\u00a0the consensus among health professionals is that affected\u00a0individuals\u00a0do not\u00a0require treatment. However, some reports to the\u00a0contrary exist, and no adequately powered study\u00a0has been completed to\u00a0verify\u00a0or refute the possible effects of diminished GALT activity\u00a0on long-term neurodevelopmental outcomes.\u00a0Duarte galactosemia may or may not be detected by newborn screening testing. [4]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Etiology. Duarte galactosemia is a variant of galactosemia due to diminished galactose-1-phosphate uridylyltransferase enzyme\u00a0activity (typically around 14% to 25%). Individuals born with Duarte variant\u00a0galactosemia are thought to be asymptomatic with or without dietary intervention, and\u00a0the consensus among health professionals is that affected\u00a0individuals\u00a0do not\u00a0require treatment. However, some reports to the\u00a0contrary exist, and no adequately powered study\u00a0has been completed to\u00a0verify\u00a0or refute the possible effects of diminished GALT activity\u00a0on long-term neurodevelopmental outcomes.\u00a0Duarte galactosemia may or may not be detected by newborn screening testing. [4]"}
{"id": "article-22025_5", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Epidemiology", "content": "Approximately 1 in 19,000 to 44,000 infants\u00a0in Europe and the United States\u00a0have galactosemia. Still, the incidence is highly variable based on ethnic background, with the highest incidence in the Irish Traveler population of approximately 1 in 480. Inheritance is autosomal recessive. [1]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Epidemiology. Approximately 1 in 19,000 to 44,000 infants\u00a0in Europe and the United States\u00a0have galactosemia. Still, the incidence is highly variable based on ethnic background, with the highest incidence in the Irish Traveler population of approximately 1 in 480. Inheritance is autosomal recessive. [1]"}
{"id": "article-22025_6", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Pathophysiology", "content": "The disaccharide lactose found in breastmilk and most infant\u00a0formulas is metabolized to the monosaccharides glucose and galactose. In galactosemia, the enzymes needed for further galactose metabolism are deficient. Classic galactosemia is caused by galactose-1-phosphate uridylyltransferase (GALT) deficiency, whereas galactokinase and UDP-galactose epimerase deficiencies may cause similar clinical consequences by disrupting the normal galactose metabolism (see figure). Ultimately, levels of galactose-1-phosphate reach toxic levels, and galactose may be alternatively reduced to its sugar alcohol form, galactitol. Galactitol is thought to cause direct damage to tissues leading to hepatomegaly, cirrhosis, renal failure, feeding intolerance, vomiting, hypoglycemia, seizure, lethargy, intellectual impairment, and cataracts. Untreated, mortality is at least 75%. Even when treated from a young age, sequelae may include cognitive or behavioral impairment, speech difficulties, low bone mineral density, ataxia or tremors, and primary ovarian insufficiency or failure in most girls. [1]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Pathophysiology. The disaccharide lactose found in breastmilk and most infant\u00a0formulas is metabolized to the monosaccharides glucose and galactose. In galactosemia, the enzymes needed for further galactose metabolism are deficient. Classic galactosemia is caused by galactose-1-phosphate uridylyltransferase (GALT) deficiency, whereas galactokinase and UDP-galactose epimerase deficiencies may cause similar clinical consequences by disrupting the normal galactose metabolism (see figure). Ultimately, levels of galactose-1-phosphate reach toxic levels, and galactose may be alternatively reduced to its sugar alcohol form, galactitol. Galactitol is thought to cause direct damage to tissues leading to hepatomegaly, cirrhosis, renal failure, feeding intolerance, vomiting, hypoglycemia, seizure, lethargy, intellectual impairment, and cataracts. Untreated, mortality is at least 75%. Even when treated from a young age, sequelae may include cognitive or behavioral impairment, speech difficulties, low bone mineral density, ataxia or tremors, and primary ovarian insufficiency or failure in most girls. [1]"}
{"id": "article-22025_7", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Toxicokinetics", "content": "Increased levels of galactose-1-phosphate due to blockage of the typical metabolic pathway are suspected to lead to alternative metabolism and direct tissue damage. Elevated levels of galactitol (galactose reduced to its sugar alcohol form) have been found in the urine of patients with galactosemia as well as tissues with evidence of damage in galactosemia. Galactose may also be oxidized to galactonate which may be a less toxic metabolite compared to accumulated galactitol. [1]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Toxicokinetics. Increased levels of galactose-1-phosphate due to blockage of the typical metabolic pathway are suspected to lead to alternative metabolism and direct tissue damage. Elevated levels of galactitol (galactose reduced to its sugar alcohol form) have been found in the urine of patients with galactosemia as well as tissues with evidence of damage in galactosemia. Galactose may also be oxidized to galactonate which may be a less toxic metabolite compared to accumulated galactitol. [1]"}
{"id": "article-22025_8", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- History and Physical", "content": "Infants with galactosemia will typically present within the first few days of life with jaundice, hepatomegaly, lethargy, and severe feeding intolerance once there is any exposure to dietary galactose in the form of breastmilk or most standard infant formulas. Additional findings may include\u00a0poor weight gain,\u00a0renal failure, coagulopathy, hypoglycemia, seizures, cerebral edema, cataracts, vitreous hemorrhage, neutropenia, and Escherichia\u00a0coli sepsis. Once diagnosed, long-term follow-up includes monitoring for cognitive and behavioral impairment, fine and gross motor delays, speech difficulties, low bone mineral density, ataxia or tremor, and primary ovarian insufficiency/failure. [1] [5]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- History and Physical. Infants with galactosemia will typically present within the first few days of life with jaundice, hepatomegaly, lethargy, and severe feeding intolerance once there is any exposure to dietary galactose in the form of breastmilk or most standard infant formulas. Additional findings may include\u00a0poor weight gain,\u00a0renal failure, coagulopathy, hypoglycemia, seizures, cerebral edema, cataracts, vitreous hemorrhage, neutropenia, and Escherichia\u00a0coli sepsis. Once diagnosed, long-term follow-up includes monitoring for cognitive and behavioral impairment, fine and gross motor delays, speech difficulties, low bone mineral density, ataxia or tremor, and primary ovarian insufficiency/failure. [1] [5]"}
{"id": "article-22025_9", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation", "content": "Newborn screening tests will identify most cases of galactosemia in developed countries. Testing evaluates for pertinent enzyme activity levels so diagnosis can be made even if testing is done before the introduction of galactose in the diet. However, if a blood transfusion has occurred before newborn screening tests, a case may be misinterpreted as being normal due to the presence of normal enzyme activity in the transfused blood.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation. Newborn screening tests will identify most cases of galactosemia in developed countries. Testing evaluates for pertinent enzyme activity levels so diagnosis can be made even if testing is done before the introduction of galactose in the diet. However, if a blood transfusion has occurred before newborn screening tests, a case may be misinterpreted as being normal due to the presence of normal enzyme activity in the transfused blood."}
{"id": "article-22025_10", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation", "content": "Severe symptoms\u00a0often manifest\u00a0within the first several days of life, before newborn screening tests may be finalized. Thus, it is important for the practitioner to maintain a high index of suspicion for inborn errors of metabolism such as galactosemia when the newborn demonstrates feeding intolerance, lethargy, and other suspicious signs like hepatomegaly renal failure, cataracts, hypoglycemia, and seizures. If there is a known risk for galactosemia in a fetus, amniocentesis or chorionic villus sampling can make or exclude a diagnosis of galactosemia before delivery.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation. Severe symptoms\u00a0often manifest\u00a0within the first several days of life, before newborn screening tests may be finalized. Thus, it is important for the practitioner to maintain a high index of suspicion for inborn errors of metabolism such as galactosemia when the newborn demonstrates feeding intolerance, lethargy, and other suspicious signs like hepatomegaly renal failure, cataracts, hypoglycemia, and seizures. If there is a known risk for galactosemia in a fetus, amniocentesis or chorionic villus sampling can make or exclude a diagnosis of galactosemia before delivery."}
{"id": "article-22025_11", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation", "content": "Postnatal newborn screening is nearly universal in the United States and Europe. However, it should be noted that some populations with the highest incidence of galactosemia also may be less likely to deliver a baby in a hospital setting. GALT enzyme activity in red blood cells or GALT gene analysis should be performed in an infant suspected of having galactosemia. Long-term, annual screening of calcium and 25-hydroxyvitamin D is recommended with supplementation as necessary following age-specific recommendations for the general population.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation. Postnatal newborn screening is nearly universal in the United States and Europe. However, it should be noted that some populations with the highest incidence of galactosemia also may be less likely to deliver a baby in a hospital setting. GALT enzyme activity in red blood cells or GALT gene analysis should be performed in an infant suspected of having galactosemia. Long-term, annual screening of calcium and 25-hydroxyvitamin D is recommended with supplementation as necessary following age-specific recommendations for the general population."}
{"id": "article-22025_12", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation", "content": "Biochemical monitoring is variable between treatment centers with most common assessments of blood galactose, RBC Gal-1-P, and/or urinary galactitol levels though it is unclear whether monitoring these levels is reflective of dietary adherence or correlates with clinical outcomes. Still, Gal-1-P levels are recommended at birth, 3 and nine months, and yearly.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation. Biochemical monitoring is variable between treatment centers with most common assessments of blood galactose, RBC Gal-1-P, and/or urinary galactitol levels though it is unclear whether monitoring these levels is reflective of dietary adherence or correlates with clinical outcomes. Still, Gal-1-P levels are recommended at birth, 3 and nine months, and yearly."}
{"id": "article-22025_13", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation", "content": "Assessment of developmental milestones, intellectual development, and speech and language assessment should be done at regular intervals such as toddler, pre-school, elementary, middle school, and high school ages. Assessment of executive function\u00a0using a standardized tool is recommended. Bone density should be assessed using bone densitometry starting around age eight to ten years and repeated every five years or sooner if low bone density is determined. If cataracts are found, a referral to an\u00a0ophthalmologist is appropriate. [1]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation. Assessment of developmental milestones, intellectual development, and speech and language assessment should be done at regular intervals such as toddler, pre-school, elementary, middle school, and high school ages. Assessment of executive function\u00a0using a standardized tool is recommended. Bone density should be assessed using bone densitometry starting around age eight to ten years and repeated every five years or sooner if low bone density is determined. If cataracts are found, a referral to an\u00a0ophthalmologist is appropriate. [1]"}
{"id": "article-22025_14", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation", "content": "More than 80% of females with classic galactosemia have primary ovarian insufficiency. [6] [7] This should be discussed\u00a0before\u00a0the typical age of puberty, and referral to a pediatric endocrinologist is appropriate to discuss the timing and need for hormone testing as well as likely hormone replacement therapy, which usually continues until the age of menopause. Males with galactosemia tend to have a normal gonadal function. Counseling regarding reproductive options should be made available to girls with primary ovarian insufficiency. [8] [5]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Evaluation. More than 80% of females with classic galactosemia have primary ovarian insufficiency. [6] [7] This should be discussed\u00a0before\u00a0the typical age of puberty, and referral to a pediatric endocrinologist is appropriate to discuss the timing and need for hormone testing as well as likely hormone replacement therapy, which usually continues until the age of menopause. Males with galactosemia tend to have a normal gonadal function. Counseling regarding reproductive options should be made available to girls with primary ovarian insufficiency. [8] [5]"}
{"id": "article-22025_15", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Treatment / Management", "content": "Treatment is the total elimination of galactose from the diet. In infants, this means cessation of breastfeeding or standard infant formula feeding and transition to non-galactose-containing formula, typically a soy-based, casein hydrolysate, or\u00a0elemental\u00a0formula. Change in the diet should be made immediately and should not be delayed to await confirmatory testing. This dietary restriction of galactose is required throughout the lifetime, although some fruits, vegetables, legumes, unfermented soy-based products, and mature cheeses with minimal galactose content may be permissible. Currently, there is no enzyme replacement or other therapy available to allow for the safe intake of galactose. [1]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Treatment / Management. Treatment is the total elimination of galactose from the diet. In infants, this means cessation of breastfeeding or standard infant formula feeding and transition to non-galactose-containing formula, typically a soy-based, casein hydrolysate, or\u00a0elemental\u00a0formula. Change in the diet should be made immediately and should not be delayed to await confirmatory testing. This dietary restriction of galactose is required throughout the lifetime, although some fruits, vegetables, legumes, unfermented soy-based products, and mature cheeses with minimal galactose content may be permissible. Currently, there is no enzyme replacement or other therapy available to allow for the safe intake of galactose. [1]"}
{"id": "article-22025_16", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Treatment / Management", "content": "In Duarte variant galactosemia, there is a debate about whether galactose intake should be restricted. Physicians or parents may choose to restrict galactose intake in infancy and early childhood, though the benefits of doing\u00a0are uncertain. [4]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Treatment / Management. In Duarte variant galactosemia, there is a debate about whether galactose intake should be restricted. Physicians or parents may choose to restrict galactose intake in infancy and early childhood, though the benefits of doing\u00a0are uncertain. [4]"}
{"id": "article-22025_17", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Differential Diagnosis", "content": "Biliary atresia Fructose 1 phosphate aldolase deficiency Fanconi Bickel syndrome Galactose kinase deficiency Hemochromatosis Hereditary fructose intolerance (HFI) Portosystemic vascular shunts Neonatal hemochromatosis", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Differential Diagnosis. Biliary atresia Fructose 1 phosphate aldolase deficiency Fanconi Bickel syndrome Galactose kinase deficiency Hemochromatosis Hereditary fructose intolerance (HFI) Portosystemic vascular shunts Neonatal hemochromatosis"}
{"id": "article-22025_18", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Prognosis", "content": "Untreated severe classic galactosemia is a life-threatening disorder. Severely ill infants with galactosemia (e.g., those with sepsis, coagulopathy, liver dysfunction) may develop permanent liver, brain, and/or eye damage (although cataracts are often completely reversible). Most patients with severe galactosemia often do not survive the newborn period if treatment is not initiated.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Prognosis. Untreated severe classic galactosemia is a life-threatening disorder. Severely ill infants with galactosemia (e.g., those with sepsis, coagulopathy, liver dysfunction) may develop permanent liver, brain, and/or eye damage (although cataracts are often completely reversible). Most patients with severe galactosemia often do not survive the newborn period if treatment is not initiated."}
{"id": "article-22025_19", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Complications", "content": "Even with the appropriate dietary therapy, most patients survive with at least 1-2 long-term complications. Almost all females with classic galactosemia present with hypergonadotropic hypogonadism/primary ovarian insufficiency (POI).", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Complications. Even with the appropriate dietary therapy, most patients survive with at least 1-2 long-term complications. Almost all females with classic galactosemia present with hypergonadotropic hypogonadism/primary ovarian insufficiency (POI)."}
{"id": "article-22025_20", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Complications", "content": "Severely ill infants with galactosemia (e.g., those with sepsis, coagulopathy, liver dysfunction) may develop permanent liver, brain, and/or eye damage (although cataracts are often completely reversible). Most patients with severe galactosemia often do not survive the newborn period if treatment is not initiated.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Complications. Severely ill infants with galactosemia (e.g., those with sepsis, coagulopathy, liver dysfunction) may develop permanent liver, brain, and/or eye damage (although cataracts are often completely reversible). Most patients with severe galactosemia often do not survive the newborn period if treatment is not initiated."}
{"id": "article-22025_21", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Deterrence and Patient Education", "content": "Both parents and children should be involved in galactose-restricted dietary therapy. Milk is better tolerated in older patients, so the pros and cons of limiting milk intake should be discussed with patients.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Deterrence and Patient Education. Both parents and children should be involved in galactose-restricted dietary therapy. Milk is better tolerated in older patients, so the pros and cons of limiting milk intake should be discussed with patients."}
{"id": "article-22025_22", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Enhancing Healthcare Team Outcomes", "content": "The diagnosis and management of galactosemia are best done with an interprofessional team that includes a pediatrician, geneticist, dietitian, social worker, primary care provider, pediatric nurse, and internist. The key is to eliminate galactose from the diet. In infants, this means cessation of breastfeeding or standard infant formula feeding and transition to non-galactose-containing formula, typically a soy-based, casein hydrolysate, or\u00a0elemental\u00a0formula. This dietary restriction of galactose is required throughout the lifetime, although some fruits, vegetables, legumes, unfermented soy-based products, and mature cheeses with minimal galactose content may be permissible. Currently, there is no enzyme replacement or other therapy available to allow for the safe intake of galactose. [1] The outcomes depend on the dietary compliance of the child. Today, there is continued debate about screening all newborns for this disorder. [3] [9]", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Enhancing Healthcare Team Outcomes. The diagnosis and management of galactosemia are best done with an interprofessional team that includes a pediatrician, geneticist, dietitian, social worker, primary care provider, pediatric nurse, and internist. The key is to eliminate galactose from the diet. In infants, this means cessation of breastfeeding or standard infant formula feeding and transition to non-galactose-containing formula, typically a soy-based, casein hydrolysate, or\u00a0elemental\u00a0formula. This dietary restriction of galactose is required throughout the lifetime, although some fruits, vegetables, legumes, unfermented soy-based products, and mature cheeses with minimal galactose content may be permissible. Currently, there is no enzyme replacement or other therapy available to allow for the safe intake of galactose. [1] The outcomes depend on the dietary compliance of the child. Today, there is continued debate about screening all newborns for this disorder. [3] [9]"}
{"id": "article-22025_23", "title": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Galactose-1-Phosphate Uridyltransferase Deficiency -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}